Tagrisso approved as adjuvant therapy for NSCLC with EGFR mutations
Tagrisso (osimertinib) received approval as an adjuvant treatment for patients with non-small cell lung cancer with epidermal growth factor receptor […]
21 December 2020 — AstraZeneca’s Tagrisso (osimertinib) has been approved in the US for the adjuvant treatment of adult patients with early-stage […] TUESDAY, Nov. 27, 2018 — Vitrakvi (larotrectinib) has been approved by the U.S. Food and Drug Administration to treat cancers […] FRIDAY, Sept. 14, 2018 — The PK Papyrus Covered Coronary Stent System has been approved by the U.S. Food and […]Approved
Tagrisso Approved in the US for the Adjuvant Treatment of Patients with Early-Stage EGFR-Mutated Non-Small Cell Lung Cancer
Vitrakvi (Larotrectinib) Approved for Cancers With Certain Genetic Trait
New Device Approved for Tears in Heart’s Blood Vessels